Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products
Biotest AG, based in Dreieich, Germany (SDAX: BIO3), specializes ininnovative hematology and immunology products. Biotest has appointed Chindexas the exclusive distributor for its unique Tango Optimo Automated Blood BankSystem for the People's Republic of China. The Tango Optimo automates allroutine testing procedures performed in blood banking, including bloodgrouping, antibody screening, and cross matching, and is the only blood bankanalyzer that offers seven-day on-board storage of liquid and microplatereagents. Upon receipt of regulatory approval from China's State Food and DrugAdministration, Chindex will market the Tango Optimo to hospital laboratoriesalong with the Johnson & Johnson Ortho Clinical Diagnostics line of clinicalchemistry analyzers.
Cutera Inc. (Nasdaq: CUTR) is a leading manufacturer of upgradeable,easy-to-use laser and other light-based aesthetic systems used by physiciansand other qualified practitioners worldwide. Under the terms of the agreement,Chindex will market and distribute the upgradeable Xeo, Solera, and CoolGlideplatforms in China and Hong Kong. The Cutera family of lasers, several ofwhich have already been registered with the Chinese State Food and DrugAdministration, provides an excellent complement to present Chindex productline.
Roberta Lipson, Chindex President and CEO, commented from Beijing, "We areexcited to be announcing these partnerships with industry-leadingmanufacturers that will widen the breadth of products that Chindex can nowoffer to China's healthcare communities. Importantly, both of these exclusiveagreements leverage our existing leadership in their respective target marketsin China. Over our 28-year history, Chindex has installed top quality medicalequipment in over 3,000 hospitals throughout China and Hong Kong, many ofwhich are repeat customers."
Today's announcement follows the Company's recently announced distributionagreement with Vital Images, Inc (Nasdaq: VTAL), a leading provider ofadvanced visualization and analysis software solutions employed byradiologists, cardiologists, oncologists, and other medical specialists tocreate 2D, 3D and 4D images of human anatomy from CT and MR image data. VitalImages' Vitrea(R) software is already approved by the State Food and DrugAdministration for sale in China, and Chindex is currently marketing theproduct to hospitals throughout China along with the innovative imagingproducts from Siemens and Hologic.
About Chindex International, Inc.
Chindex is an American healthcare company that provides healthcareservices and supplies medical capital equipment, instrumentation and productsto the Chinese marketplace, including Hong Kong. Healthcare services areprovided through the operations of its United Family Hospitals and Clinics, anetwork of private primary care hospitals and affiliated ambulatory clinics inChina. The Company's hospital network currently operates in the Beijing,Shanghai, Guangzhou and Wuxi. The Company sells medical products manufacturedby various major multinational companies, including Siemens AG and IntuitiveSurgical, for which the Company is the exclusive distribution partner for thesale and servicing of color ultrasound systems and surgical robotic systemsrespectively. It also arranges financing packages for the supply of medicalproducts to hospitals in China utilizing the export loan and loan guaranteeprograms of both the U.S. Export-Import Bank and the German KfW DevelopmentBank. With twenty-seven years of experience, approximately 1,300 employees,and operations in China, Hong Kong, the United States and Germany, theCompany's strategy is to expand its cross-cultural reach by providing leadingedge healthcare technologies, quality products and services to Greater China'sprofessional communities. Further company information may be found at theCompany's websites http://www.chindex.com andhttp://www.unitedfamilyhospitals.com .
Safe Harbor Statement
Statements made in this press release relating to plans, strategies,objectives, economic performance and trends and other statements that are notdescriptions of historical facts may be forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended (the"Securities Act"), and Section 21E of the Securities Exchange Act of 1934, asamended (the "Exchange Act"). Forward-looking information is inherentlysubject to risks and uncertainties, and actual results could differ materiallyfrom those currently anticipated due to a number of factors, which include,but are not limited to, the factors set forth under the heading "Risk Factors"in our annual report on Form 10-K for the year ended March 31, 2009, updatesand additions to those "Risk Factors" in our interim reports on Form 10-Q,Forms 8-K and in other documents filed by us with the Securities and ExchangeCommission from time to time. Forward-looking statements may be identified byterms such as "may," "will," "should," "could," "expects," "plans," "intends,""anticipates," "believes," "estimates," "predicts," "forecasts," "potential,"or "continue" or similar terms or the negative of these terms. Although webelieve that the expectations reflected in the forward-looking statements arereasonable, we cannot guarantee future results, levels of activity,performance or achievements. We have no obligation to update theseforward-looking statements.For further information, please contact: Integrated Corporate Relations Ashley M. Ammon Tel: +1-203-682-8200
SOURCE Chindex International, Inc.
You May Also Like